+ acute lymphoblastic leukemia patients have transient responses to current therapies. However, the fusion of BCR to ABL generates a potential leukemia-specific Ag that could be a target for immunotherapy. We demonstrate that the immune system can limit BCR-ABL + leukemia progression although ultimately this immune response fails. To address how BCR-ABL + leukemia escapes immune surveillance, we developed a peptide: MHC class II tetramer that labels endogenous BCR-ABL-specific CD4 + T cells. Naive mice harbored a small population of BCR-ABL-specific T cells that proliferated modestly upon immunization. The small number of naive BCR-ABL-specific T cells was due to negative selection in the thymus, which depleted BCR-ABLspecific T cells. Consistent with this observation, we saw that BCR-ABL-specific T cells were cross-reactive with an endogenous peptide derived from ABL. Despite this cross-reactivity, the remaining population of BCR-ABL reactive T cells proliferated upon immunization with the BCR-ABL fusion peptide and adjuvant. In response to BCR-ABL + leukemia, BCR-ABL-specific T cells proliferated and converted into regulatory T (Treg) cells, a process that was dependent on cross-reactivity with self-antigen, TGFb1, and MHC class II Ag presentation by leukemic cells. Treg cells were critical for leukemia progression in C57BL/6 mice, as transient Treg cell ablation led to extended survival of leukemic mice. Thus, BCR-ABL + leukemia actively suppresses antileukemia immune responses by converting cross-reactive leukemia-specific T cells into Treg cells. The Journal of Immunology, 2015, 195: 4028-4037. C ancer immunotherapy is an effective clinical approach in malignancies with high rates of nonsynonymous mutations (1-4). Most cancer immunotherapy approaches currently focus on neo-antigen-specific T cells, which ideally respond to mutations in proteins that drive tumorigenesis (5-8). However, identifying nonsynonymous immunogenic mutations in driver genes is not always possible, thereby necessitating the use of either multiple Ags, or cross-reactive self-antigens, to prevent immune escape. This problem is illustrated in B cell acute lymphoblastic leukemia (B-ALL), which has few nonsynonymous mutations (9). However, B-ALL is characterized by chromosomal translocations that give rise to fusion proteins encoding neoantigens that drive transformation (10). We focused on BCR-ABL + B-ALL, which creates a neo-antigen at the fusion of BCR to ABL. Immunotherapy is an attractive goal in BCR-ABL + B-ALL because current therapies elicit only transient responses and long-term survival is poor. CD4 + T cells from patients with BCR-ABL + B-ALL can secrete IFN-g upon ex vivo restimulation with peptides from the BCR-ABL fusion, but these responses are inadequate to eradicate leukemia in vivo (11, 12). To understand why BCR-ABL-specific immunity fails to eliminate BCR-ABL + B-ALL in mice, we identified BCR-ABL-specific CD4 + T cells and tracked their responses to leukemia in vivo.
C
ancer immunotherapy is an effective clinical approach in malignancies with high rates of nonsynonymous mutations (1) (2) (3) (4) . Most cancer immunotherapy approaches currently focus on neo-antigen-specific T cells, which ideally respond to mutations in proteins that drive tumorigenesis (5) (6) (7) (8) . However, identifying nonsynonymous immunogenic mutations in driver genes is not always possible, thereby necessitating the use of either multiple Ags, or cross-reactive self-antigens, to prevent immune escape. This problem is illustrated in B cell acute lymphoblastic leukemia (B-ALL), which has few nonsynonymous mutations (9) . However, B-ALL is characterized by chromosomal translocations that give rise to fusion proteins encoding neoantigens that drive transformation (10) . We focused on BCR-ABL + B-ALL, which creates a neo-antigen at the fusion of BCR to ABL. Immunotherapy is an attractive goal in BCR-ABL + B-ALL because current therapies elicit only transient responses and long-term survival is poor. CD4 + T cells from patients with BCR-ABL + B-ALL can secrete IFN-g upon ex vivo restimulation with peptides from the BCR-ABL fusion, but these responses are inadequate to eradicate leukemia in vivo (11, 12) . To understand why BCR-ABL-specific immunity fails to eliminate BCR-ABL + B-ALL in mice, we identified BCR-ABL-specific CD4 + T cells and tracked their responses to leukemia in vivo.
To examine antileukemia T cell responses, we made use of a BCR-ABL + B-ALL mouse model that recapitulates the human disease (13) . To track antileukemia T cell responses, we generated a BCR-ABL peptide (BAp):MHC class II (MHC-II) tetramer reagent. We demonstrate that an adaptive immune response is elicited against BCR-ABL + B-ALL, and this response limits leukemia progression. 
Materials and Methods
Mice C57BL/6 (B6) mice and Cdkn2a 2/2 [strain 01XF6, B6, and 129-Cdkn2a tm1Cjs /Nci (14) ] mice came from the National Cancer Institute. Foxp3-GFP (stock number 006772) mice came from The Jackson Laboratory (Bar Harbor, ME). Bim 
Leukemia model
The BCR-ABL + B acute lymphoblastic leukemia model has been described previously (20) . Briefly, Cdkn2a 2/2 mouse bone marrow (BM) cells were transduced with viral supernatant containing a BCR-ABL (P190)-internal ribosome entry site (IRES)-GFP retrovirus (21) . Cells were cultured in RPMI 1640 medium + 10% FBS + 1% penicillin-streptomycin + 1% L-glutamine + 0.001% 2-ME in a 37˚C incubator. A total of 2500 live cells were adoptively transferred i.v. into host mice without prior irradiation. The SP1 cells were derived from leukemia in a STAT5bCAx-Pax5 +/2 mouse as described previously (22 
Tetramer production
The BAp:I-A b tetramer and others used in this study were produced as described previously (23) . Purified monomer was tetramerized with streptavidin-PE or streptavidin-allophycocyanin.
Ag-specific CD4
+ T cell enrichment strategy I-A b tetramer-binding cell enrichment was performed as described previously (23) . Tetramers loaded with PE and allophycocyanin were used together, and tetramer double-positive events were analyzed to increase sensitivity and specificity (24) . Cells were enriched with either Miltenyi or StemCell anti-allophycocyanin and anti-PE reagents following manufacturer's protocols. The enriched fractions were mixed with Accucheck counting beads (Life Technologies, Grand Island, NY) for cell enumeration.
Histology
Histology was performed as previously described and Abs are listed below (25) .
Abs
Abs for flow cytometry and histology include CD3 PE, CD4 (RM4-5) PerCPCy5.5, CD8 (53-6.7) BV650, CD11c (N418) PE, and FOXP3 (FJK16S) PE were purchased from BD Biosciences (San Jose, CA); NK1.1 (PK136), CD11b (M1/70), CD11c (N418), B220 (RA3-6B2), and F4/80 in allophycocyanin-eFluor780; PD1 (J43) FITC, CD73 eFluor450, FR4 PECy7, PDL1 PerCP-eFluor710, MHC-II I-Ab eFluor450, IL7R PE, and all ELISPOT Abs were purchased from eBioscience (San Diego, CA); and IgM (Fab9)a l l o p h y c o c y a n i nw a sp u r c h a s e df r o mJ a c k s o nI m m u n o r e s e a r c hL a b oratories (West Grove, PA). Rat IgG1 (HRPN) PerCP-Cy5.5 Isotype and Rat IgG2a (2A3) violetFluor450 Isotype were purchased from Tonbo Biosciences (San Diego, CA). Cells from enriched fractions were analyzed on an LSR-II Fortessa cytometer (BD Biosciences, San Jose CA), and data were analyzed in FlowJo (Tree Star, Ashland OR). Intracellular cytokine staining was done using BD Cytofix/Cytoperm reagents and protocols (BD Biosciences). Anti-IL-10 (JES5-16E3, PE; eBioscience), TGFB1(LAP) (TW7-16B4, ef710; eBioscience), IFN-g (XMG1.2, BV421; BD Horizon), and TNF-a (MP6-XT22, AF488; eBioscience) were stained by this procedure.
ELISPOT
B6 mice were immunized with e1a2 peptide (GEGAFHGDAEALQRP-VASDF; 2 mg/ml) or 2W1S peptide (EAWGALANWAVDSA; 0.2 mg/ml) emulsified in CFA (Sigma-Aldrich, St. Louis, MO) and harvested 2 wk later. CD4 + T cells were enriched using a mouse CD4 T cell Isolation Kit (Miltenyi Biotec, Bergisch Gladbach, Germany). Naive mouse splenocytes were harvested, irradiated, and mixed at a 1:1 ratio with the immunized CD4 + T cells in wells coated with IFN-g capture Ab (AN-18) at a concentration of 15 mg/ml. Synthetic overlapping peptides that spanned the BCR-ABL p190 fusion (Genscript, Piscataway, NJ) were added to individual wells. 2W1S peptide and Con A were used as positive controls. Samples were developed using a biotinylated IFN-g detection Ab (R4-6A2) and streptavidin-alkaline phosphatase with 5-bromo-4-chloro-3-indolyl phosphate and NBT developing agents and photographed and analyzed with a ImmunoSpot S6 Microanalyzer using the ImmunoCapture 6.3 and ImmunoSpot 5.0 Pro DC software (Cellular Technology, Shaker Heights, OH).
Statistics
Standard normality tests suggested departures from normality, so nonparametric tests (Mann-Whitney U test for two groups, Kruskal-Wallis, and Dunns' test for more than two groups) were used unless otherwise stated. Normality assessments and nonparametric tests were done in GraphPad Prism (La Jolla, CA). Linear regressions and correlation coefficients were estimated in GraphPad Prism.
Results
The adaptive immune system mounts a response to BCR-ABL
+ leukemia
To examine whether BCR-ABL + leukemia elicited an adaptive immune response in mice, we adoptively transferred Cdkn2a
2/2
BCR-ABL + pre-B cells into healthy, immune-competent recipient mice. This model incorporates two genetic alterations common in high-risk human B-ALL: BCR-ABL and loss of the tumor suppressor ARF (26) . Furthermore, these cells can be transferred into unconditioned host mice where they faithfully form B-ALL (20) . The leukemic cells express CD19, B220, IL-7R, MHC-II, and low levels of IgH and therefore closely resemble human progenitor B-ALL (Fig. 1A) . In syngeneic (B6) hosts, leukemia arose in the BM and the splenic red pulp with small numbers of leukemic cells in the lymph nodes (Fig. 1B-D) .
To determine whether the adaptive immune system had any control over BCR-ABL + B-ALL progression, we compared leukemic cell counts (referred to hereafter as leukemic burden) in B6 and OT-IxRag2 2/2 mice. OT-IxRag2 2/2 mice were used because they have T cells but no leukemia-specific adaptive immunity. The percentage of leukemic (CD45.1 + GFP + ) B cells in the BM was significantly higher in OT-IxRag2 2/2 mice than in B6 mice (Fig. 1E ).
BAp:I-A b -specific T cells in naive mice
We studied the interaction between BCR-ABL + B-ALL and CD4 + T cells by tracking leukemia-specific T cells. Because BCR-ABL is a somatic mutation, the peptide spanning the fusion of BCR to ABL could potentially elicit a T cell response. Using an ELISPOT assay, we found a MHC-II binding peptide in the BCR-ABL fusion that elicited a CD4 + T cell response ( T cell-based cancer immunotherapy is thought to be more effective when T cells recognize cancer cell neo-antigens with minimal cross-reactivity for self-antigens. Thus, we addressed whether -specific T cells recognized neo-antigens or cross-reactive self-antigens. Recent studies have shown that small peptide:MHC-II-specific T cell repertoires are predictive of cross-reactivity with self-antigen (27) . The BAp peptide (DAEALQRPVASDF) closely resembles the endogenous ABL peptide (LEEALQRPVASDF) (85% identical, see underlined portion), so we tested whether BAp:I-A b tetramer-binding T cells could recognize the overlapping ABL peptide. When mice were immunized with adjuvant plus ABL peptide, BAp:I-A b tetramer-binding cells proliferated 46-fold, which is similar to the proliferation seen after immunization with BAp peptide plus adjuvant (Fig. 2G, 2H ). Taken together, this evidence suggests that BAp:I-A b -binding T cells are cross-reactive with the self-peptide ABL. These results may explain the occasional expression of CD44 that we saw on BAp:I-A bspecific T cells in naive mice.
BAp:I-A b specific T cell numbers in naive mice are controlled by central tolerance
The precursor frequency of BAp:I-A b -specific T cells was quite low (Fig. 2D) ; thus, we examined whether immune central tolerance may be limiting the number of BAp:I-A b -specific T cells in naive mice. Bim 2/2 mice, which have defective thymic negative selection, had significantly (∼5-fold) more BAp:I-A b -specific T cells (Fig. 3A) (18, 28, 29) . Thus, ∼80% of the BAp:I-A bspecific T cell progenitors were deleted during thymic negative selection.
We next reasoned that the BAp:I-A b -specific T cell clones, which were rescued in Bim 2/2 mice, might have high affinity for cognate BAp:I-A b . To examine this issue, we analyzed the tetramer mean fluorescence intensity of BAp:I-A b tetramer-binding cells and normalized this value to that found in the matching bulk CD4 + T cell compartment. Interestingly, we found that the tetramer mean fluorescence intensity was significantly higher in the B6 mice than in the Bim 2/2 mice (Fig. 3B) . In addition, when we immunized Bim 2/2 mice with BAp peptide emulsified in CFA, we saw no increase in the number of BAp:I-A b -specific T cells recovered from Bim 2/2 mice ( b -specific T cell count. The number above the line is the fold change from median (indicated by black bars). All fold expansions shown resulted in significantly higher T cell counts than in unimmunized mice; more than two independent experiments were conducted for each immunization shown. (H) B6 mice were immunized with BAp peptide or ABL peptide emulsified in CFA. Fourteen days later, secondary lymphoid organs were harvested as described previously. y-axis is the Log (Y+1) of BAp:I-A b tetramerbinding events; data are from three independent experiments. All comparisons were made with Kruskal-Wallis test (more than two groups). b -specific T cell-to-leukemic cell ratio (Fig. 4D) . Thus, the proliferation of neo-antigen-specific T cells responding to BCR-ABL + B-ALL is inhibited.
T cells specific for cross-reactive leukemia Ags are converted into pTreg cells by leukemia
Our studies provide evidence that BAp:I-A b -specific T cells respond to BCR-ABL + B-ALL despite cross-reactivity with selfantigen. However, leukemia still progresses in B6 mice, which suggests that mechanisms of tolerance inhibit the immune responses by cross-reactive T cells. Indeed, BAp:I-A b -specific T cells positively correlated with leukemic burden in naive mice inoculated with leukemia (Fig. 5A) (Fig. 5B ). This contrast supports the conclusion that B-ALL converts BAp:I-A b -specific T cells into pTreg cells and provides a mechanism for host tolerance of leukemia.
We next determined whether leukemia-specific Treg polarization was related to the cross-reactivity of BAp:I-A b -specific T cells with self-antigen. To address this question, we examined both neo-antigen-specific T cells and cross-reactive T cells responding to leukemia. The leukemic cells used in these experiments express both GFP and BCR-ABL, and thus, GFP was a leukemia-specific neo-antigen in B6 mice and BCR-ABL was a cross-reactive Ag in B6 mice. We enumerated GFP:I-A b -specific Treg cells responding to leukemia in Foxp3-RFP mice (where GFP is a non-self-Ag) and Fig. 5C ). Importantly, 75% of naive Foxp3-GFP mice contained no GFP:I-A b -specific Treg cells (Fig. 5D ), suggesting that GFP:I-A b -specific Treg cells seen in leukemic Foxp3-GFP mice were induced Treg cells. Thus, peripheral CD4 + T cells that cross-react with self have increased capacity to become pTreg cells in response to leukemia. Histologically, Treg cells were localized in the splenic red pulp, adjacent to red pulp macrophages and leukemic cells (Fig. 5E, 5F ). Red pulp macrophages have been shown to induce Treg cells in vitro (31) . Thus, Treg cells responding to leukemia Ags are preferentially cross-reactive and localized in an immune-suppressive microenvironment near the leukemic cells.
Treg cells allow leukemia progression in B6 mice
To determine whether Treg cells inhibited the immune response to BCR-ABL + leukemia, we selectively ablated Treg cells using Foxp3 DTR/DTR mice (17) . Transient depletion of Treg cells led to a 98% decrease in leukemic burden in the BM at 14 d postinoculation with leukemia (Fig. 6A, 6B) . Depletion of Treg cells during the first 14 d following leukemia inoculation also led to an increased survival of mice as compared with untreated B6 mice (Fig. 6C) . In parallel, BAp:I-A b -specific T cells proliferated ∼30-fold more in DT-treated Foxp3 DTR/DTR mice than in DT-treated B6 mice (Fig. 6D) .
We next sought mechanistic insight into how the presence of Treg cells inhibited the leukemia-specific immune response. We found that the percent of BAp:I-A b -specific T cells that were CD44 hi was significantly higher in DT-treated Foxp3 (Fig. 6E) . We reasoned that Ly6C + Th1-like cells might also be important in controlling leukemia progression (32) (33) (34) . Indeed, the fraction of CD44 + and Ly6C + BAp:I-A b -specific T cells was increased in DT-treated Foxp3 DTR/DTR mice, suggesting that Treg cells inhibit BAp:I-A b -specific T cell priming and effector differentiation during the immune response to leukemia (Fig. 6F) .
Treg conversion in response to leukemia is dependent on TGF-b and Ag presentation by leukemic cells
Treg cells were clearly important for leukemia progression (Fig. 6F) . However, the mechanism that drives BAp:I-A b -specific T cells into the Treg lineage in mice with leukemia remains unclear. One possible explanation is that the leukemic cells might produce cytokines that drive Treg conversion. To address this point, we analyzed cytokines production by leukemic cells and by BAp:I-A b -specific T cells responding to leukemia. When responding to leukemia, both leukemic cells and BAp:I-A bspecific T cells produced the immune-suppressive cytokines IL-10 and TGF-b1 (Fig. 7A-F (Figs. 4A, 7G, 7H ). These results suggested that TGF-b1 was critical for efficient induction of leukemiaspecific Treg cells in this model.
Leukemic cells and Treg cells were also in relatively close contact in the splenic red pulp (Fig. 5F ). Thus, we reasoned that the leukemic cells might present Ag in the context of MHC-II, and initiate Treg induction by simultaneously providing TGF-b1. To test this hypothesis, we generated MHC-II (Fig. 7I, 7J ). In addition, 
MHC-II
2/2 leukemia correlated with significantly more proliferation of BAp:I-A b -specific T cells in leukemic mice (Fig. 7H) , again suggesting that the decreased BAp:I-A b -specific Treg conversion might allow for increased proliferation of the BAp:I-A b -specific Tc e l l s .C o n s i s t e n tw i t ht h e s efi ndings, we observed a significant increase in survival of mice inoculated with MHC-II 2/2 leukemia compared with MHC-II replete leukemia (Fig. 7K) . 
Discussion
Recent studies demonstrate that augmenting immune responses can be an effective treatment for cancer (6, (37) (38) (39) (40) . Although the immune system recognizes both tumor-associated self-antigens and tumor-specific neo-antigens, cell-based immunotherapy approaches have focused on using neo-antigen-specific T cells, which should not be subject to immune tolerance. Many of these approaches use mutations arising in the malignancy that may not drive cancer progression, thus potentially allowing immune escape. Furthermore, most of these treatments have been used in cancers with many nonsynonymous mutations. In this study, we examine the immune response to a cancer with few nonsynonymous mutations by investigating the adaptive immune response to the oncoprotein BCR-ABL. Our approach was informed by using BAp:I-A b tetramers to track cross-reactive leukemia-specific T cells and GFP:I-A b tetramers to track neo-antigen-specific T cells. A major finding from our studies is that BCR-ABL + leukemia induces tolerance to both cross-reactive tumor associated self-antigens and tumor-specific neo-antigens. However, the mechanism of tolerance differed depending on whether the tumor-derived Ag was a cross- A key question in cancer immunotherapy is whether T cell tolerance can be prevented or reversed. Our findings demonstrate that BCR-ABL-specific tolerance can be limited by Treg depletion, which correlates with increased expression of Ly6C on the BAp:I-A b -specific T cells. Ly6C is expressed on Th1-like effector cells that produce high levels of IFN-g, IL-2, and granzyme B (33) . Importantly, Th1 cells are classically thought to be critical for tumor control (41) . Thus, our data suggest that LY6C (Fig. 7G, 7H) .
Temporal regulation of TGF-b1 production by leukemic cells and BAp:I-A b -specific T cells remains to be ascertained in this model. One likely model is that initial TGF-b1 production by the leukemic cells induces BAp:I-A b -specific Treg conversion, which then produce TGF-b1 as well. In this model, leukemic cell-derived Ag presentation and TGF-b1 initiate Treg conversion, and BAp:I-A b -specific T cell-derived TGF-b1 maintains Treg polarization. Importantly, such a mechanism would allow BAp:I-A bspecific Treg cells to suppress proliferation of other anti-leukemia Tc e l l sv i aT G F -b1( s u c ha sG F P : I -A b -specific T cells in our model).
Regardless of the temporal expression patterns of TGF-b1, the data presented in this paper point to the importance of the leukemia microenvironment. Specifically, the leukemia microenvironment has copious amounts of TGF-b as well as Ag presentation by the leukemic cells,whichprotectstheleukemia from the host immune response. This model requires leukemic cells to present Ag on MHC-II as well as produce TGF-b1, thus suggesting that these two mechanisms may synergize to induce immune suppression.
Our findings provide evidence that Treg depletion can modestly extend survival of leukemic mice and that this correlates with increased priming and Th1 skewing of BAp:I-A b -specific T cells. Finally, even though current immunotherapy is largely focused on tumor neo-antigens, our studies support the notion that crossreactive T cells can play a role in the immune response to leukemia. Therefore, our work may inform future therapeutic options that are aimed at reducing the number or function of Treg cells present in cancer.
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